Terms: = Ovarian cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Staging
14 results:
1.
Rahmanian N; Hosseinimehr SJ; Khalaj A; Noaparast Z; Abedi SM; Sabzevari O
Daru; 2017 May; 25(1):13. PubMed ID: 28464952
[TBL] [Abstract] [Full Text] [Related]
2. Setting the bar: compliance with ovarian cancer quality indicators at a National cancer Institute-designated Comprehensive cancer Center.
Liang MI; ElNaggar AC; Nekkanti S; O'Malley DM; Hade EM; Copeland LJ; Fowler JM; Salani R; Backes FJ; Cohn DE
Gynecol Oncol; 2015 Sep; 138(3):689-93. PubMed ID: 26216728
[TBL] [Abstract] [Full Text] [Related]
3. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination.
Viana Lde S; Affonso RJ; Silva SR; Denadai MV; Matos D; Salinas de Souza C; Waisberg J
Oncology; 2013; 84(2):81-91. PubMed ID: 23128103
[TBL] [Abstract] [Full Text] [Related]
4. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract] [Full Text] [Related]
5. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract] [Full Text] [Related]
6. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
Han ES; Lin P; Wakabayashi M
Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Skírnisdóttir I; Seidal T; Karlsson MG; Sorbe B
Int J Oncol; 2005 Jan; 26(1):177-83. PubMed ID: 15586238
[TBL] [Abstract] [Full Text] [Related]
8. A new prognostic model comprising p53, egfr, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract] [Full Text] [Related]
9. c-erbb-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of DNA quantification in early epithelial ovarian carcinoma.
Valverde JJ; Martin M; García-Asenjo JA; Casado A; Vidart JA; Díaz-Rubio E
Obstet Gynecol; 2001 Mar; 97(3):409-16. PubMed ID: 11239647
[TBL] [Abstract] [Full Text] [Related]
11. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract] [Full Text] [Related]
12. Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.
Rabczyński J; Ziółkowski P
Pathol Oncol Res; 1999; 5(1):61-6. PubMed ID: 10079381
[TBL] [Abstract] [Full Text] [Related]
13. Serum serbb1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract] [Full Text] [Related]
14. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract] [Full Text] [Related]
